Biotech’s Uncomfortable Adolescence: Capital Is Back, But the Industry Has Changed Permanently
Biotech VC hit $26B in 2024 as IPOs lagged and China licensing surged—here's what the recovery's structure reveals about...
China Biotech
The China Oncology Pipeline Is Going Global — And Pfizer Just Fired the Starting Gun
Pfizer's deal with Innovent Biologics joins a pattern of Western pharma betting on Chinese oncology pipelines to fill post-LOE...
China Biotech Deal Volume Surged 81% as Western Pharma Doubles Down
A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...